Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...
Biolexis Therapeutics Unlocks a New Frontier in GLP-1 Receptor Activation
Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...
BioSpace7d
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...
Morningstar10d
Biolexis Therapeutics Unlocks a New Frontier in GLP-1 Receptor Activation
structure of BLX-7006, its first-in-class oral small-molecule GLP-1 receptor agonist. This breakthrough confirms a completely novel allosteric activation mechanism for the GLP-1 receptor ...
BioSpace6d
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic
Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.
MedPage Today29d
GLP-1 Receptor Agonists for Diabetes Tied to Slightly Lower Depression Risk
Duration of GLP-1 receptor agonist use and depression risk ... insulin use, or molecular structure of GLP-1 agonist agent (semaglutide [Ozempic], liraglutide [Victoza], dulaglutide [Trulicity ...
Hosted on MSN28d
GLP-1 Receptor Agonists for Diabetes Tied to Slightly Lower Depression Risk
Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower ... insulin use, or molecular structure of GLP-1 agonist agent (semaglutide [Ozempic], liraglutide [Victoza], dulaglutide ...